Evidence map›Paper›PMID 35563543›Full record

ArticleInternational journal of molecular sciences2022

Profiling the Biological Characteristics and Transitions through Upper Tract Tumor Origin, Bladder Recurrence, and Muscle-Invasive Bladder Progression in Upper Tract Urothelial Carcinoma.

Keisuke Shigeta, Kazuhiro Matsumoto, Nobuyuki Tanaka, Shuji Mikami, Takeo Kosaka, Yota Yasumizu, Toshikazu Takeda, Ryuichi Mizuno, Eiji Kikuchi, Mototsugu Oya

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Keisuke ShigetaDepartment of Urology, Keio University School of Medicine, Tokyo 160-8582, Japan.
Kazuhiro MatsumotoDepartment of Urology, Keio University School of Medicine, Tokyo 160-8582, Japan.ORCID 0000-0001-9222-0999
Nobuyuki TanakaDepartment of Urology, Keio University School of Medicine, Tokyo 160-8582, Japan.
Shuji MikamiDivision of Diagnostic Pathology, Keio University School of Medicine, Tokyo 160-8582, Japan.ORCID 0000-0002-2978-2187
Takeo KosakaDepartment of Urology, Keio University School of Medicine, Tokyo 160-8582, Japan.
Yota YasumizuDepartment of Urology, Keio University School of Medicine, Tokyo 160-8582, Japan.
Toshikazu TakedaDepartment of Urology, Keio University School of Medicine, Tokyo 160-8582, Japan.ORCID 0000-0003-1196-8642
Ryuichi MizunoDepartment of Urology, Keio University School of Medicine, Tokyo 160-8582, Japan.
Eiji KikuchiDepartment of Urology, St. Marianna University School of Medicine, Kanagawa 216-8511, Japan.
Mototsugu OyaDepartment of Urology, Keio University School of Medicine, Tokyo 160-8582, Japan.

Funding

Japanese Foundation for Research and Promotion of Endoscopy 2020Japan Society for the Promotion of Science KAKENHI JP18K09179the Japan Society for the Promotion of Science KAKENHI JP 21K20811
6 · The paper itself

Abstract

To evaluate biological characteristics and transitions of upper tract urothelial carcinoma (UTUC) through metachronous bladder tumors after radical nephroureterectomy (RNU), we conducted immunohistochemical (IHC) staining of tumor specimens of UTUC tumor origin, non-muscle-invasive bladder cancer (NMIBC) and MIBC progressed after intravesical recurrence (IVR), and bladder primary MIBC. Fibroblast growth factor receptor 3 (FGFR3), p53, cytokeratin 5/6 (CK5/6), and CK20 were stained to examine expression rates. After expression assessment with heatmap clustering, the overexpression of four biomarkers from UTUC origin to metachronous MIBC progression was analyzed with clinicopathological variables. We found that high CK20 and low CK5/6 expression were both observed in UTUC tumor origin and subsequent NMIBC after RNU. By investigating molecular expression in the IVR specimen, we observed that low pT stage bladder recurrence occupied the majority of CK20 high CK5/6 low expression, but would change to CK20 low CK5/6 high expression as it progressed to MIBC. UTUC metachronous MIBC has different characteristics compared with bladder primary MIBC, which comprises favorable biological features such as high FGFR3 expression, and follows favorable prognosis compared to those without FGFR3 expression. The present study demonstrated that the biological characteristics of UTUC tumor origin shifts from luminal to basal-like features with progression to MIBC, but FGFR3 expression taken over from UTUC origin may comprise a favorable entity compared to primary MIBC.

Indexed as

Carcinoma, Transitional CellNeoplasms, Second PrimaryUrinary Bladder NeoplasmsUrologic NeoplasmsFemaleHumansMaleMusclesNeoplasm Recurrence, LocalRetrospective StudiesUrinary Bladderfibroblast growth factor receptor 3intravesical recurrencemolecular characteristicmuscle-invasive bladder carcinomaupper tract urothelial carcinoma

Identifiers

PMID35563543
PMCPMC9105227

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.